Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4472794 | 0.83 | RARB (0.44) | L3MBTL1KDM4ENFKB1MEN1ALDH1A1 | |
| SCHEMBL29893529 | 0.82 | KDM4E (0.33) | KDM4EALDH1A1MAPT | |
| SCHEMBL17584302 | 0.80 | — | — | |
| SCHEMBL23162740 | 0.77 | NQO1 (0.37) | L3MBTL1KDM4EALDH1A1CYP3A4MAPT | |
| SCHEMBL14719126 | 0.77 | CASP3 (0.36) | KDM4EALDH1A1LMNACYP1A2CYP3A4 | |
| SCHEMBL109668 | 0.77 | CYP2D6 (0.34) | L3MBTL1KDM4EALDH1A1LMNACYP1A2 | |
| SCHEMBL22498772 | 0.76 | SPHK1 (0.34) | — | |
| SCHEMBL31612663 | 0.76 | AR (0.32) | ALDH1A1MAPK1 | |
| SCHEMBL2178833 | 0.76 | L3MBTL1 (0.38) | L3MBTL1KDM4ENFKB1MEN1ALDH1A1 | |
| SCHEMBL29060387 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4038064-B1 | N-SUBSTUTUTED-6-OXO-1,6-DIHYDROPYRIMIDINE-2-YL DERIVATIVES AS INHIBITORS OF THE HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2024-02-21 | — | — | EP | disclosed |
| US-20220409619-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2022-12-29 | — | — | US | disclosed |
| EP-4038064-A1 | N-SUBSTUTUTED-6-OXO-1,6-DIHYDROPYRIMIDINE-2-YL DERIVATIVES AS INHIBITORS OF THE HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2022-08-10 | — | — | EP | disclosed |
| WO-2021064570-A1 | N-SUBSTUTUTED-6-OXO-1,6-DIHYDROPYRIMIDINE-2-YL DERIVATIVES AS INHIBITORS OF THE HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2021-04-08 | — | — | WO | disclosed |
| EP-3227303-B1 | BICYCLIC COMPOUNDS AS PEST CONTROLLERS | BAYER CROPSCIENCE AG (DE) | 2018-10-24 | — | — | EP | disclosed |
| US-20180282347-A1 | BICYCLIC COMPOUNDS AS PEST CONTROL AGENTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-10-04 | — | — | US | disclosed |
| EP-3227301-A1 | BICYCLIC COMPOUNDS AS PEST CONTROL AGENTS | Bayer CropScience AG (DE) | 2017-10-11 | — | — | EP | disclosed |
| EP-3227303-A1 | BICYCLIC COMPOUNDS AS PEST CONTROL AGENTS | Bayer CropScience AG (DE) | 2017-10-11 | — | — | EP | disclosed |
| US-20170265474-A1 | BICYCLIC COMPOUNDS AS PEST CONTROL AGENTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-09-21 | — | — | US | disclosed |
| WO-2016087418-A1 | BICYCLIC COMPOUNDS AS PEST CONTROL AGENTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016087417-A1 | BICYCLIC COMPOUNDS AS PEST CONTROL AGENTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2016-06-09 | — | — | WO | disclosed |
| EP-1442036-B1 | HETEROARYL DERIVATIVES AS SUPERIOR LIGANDS FOR NOCICEPTIN RECEPTOR ORL-1 | SCHERING CORP (US) | 2006-01-11 | — | — | EP | disclosed |
| EP-1442036-A2 | HETEROARYL DERIVATIVES AS SUPERIOR LIGANDS FOR NOCICEPTIN RECEPTOR ORL-1 | SCHERING CORPORATION (US) | 2004-08-04 | — | — | EP | disclosed |
| US-6727254-B2 | 8-(BIS-(PHENYL) METHYL)-3-HETEROARYL-8-AZABICYCLO-(3.2.1)OCTAN-3-OLS AND DERIVATIVES, USEFUL IN TREATING PAIN, ANXIETY, COUGH, ASTHMA, DEPRESION AND ALCOHOL ABUSE | SCHERING CORPORATION | 2004-04-27 | — | — | US | disclosed |
| US-20030119847-A1 | Heteroaryl derivatives as superior ligands for nociceptin receptor ORL-1 | SCHERING CORPORATION | 2003-06-26 | — | — | US | disclosed |
| WO-2003039469-A2 | HETEROARYL DERIVATIVES AS SUPERIOR LIGANDS FOR NOCICEPTIN RECEPTOR ORL-1 | SCHERING CORPORATION (US) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170265474-A1 | BICYCLIC COMPOUNDS AS PEST CONTROL AGENTS | DDT, BCHE, BAK1 | L3MBTL1 169/4885KDM4E 1943/4885NFKB1 2765/4885 |
| US-20180282347-A1 | BICYCLIC COMPOUNDS AS PEST CONTROL AGENTS | DDT, BCHE, BAK1 | L3MBTL1 169/4885KDM4E 1943/4885NFKB1 2765/4885 |
| US-20220409619-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2E, POLR2H | L3MBTL1 2208/4885KDM4E 1977/4885NFKB1 466/4885 |
| US-20030119847-A1 | Heteroaryl derivatives as superior ligands for nociceptin receptor ORL-1 | OPRL1, OPRD1, OPRK1 | L3MBTL1 693/4885KDM4E 4829/4885NFKB1 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.